Последние отзывы
ВИДАТОКС - VIDATOX - 4 шт.
ВИДАТОКС - VIDATOX - 4 шт.
Отзывы
Вычитал, что Видатокс широко применяется на Кубе для очистки и восстановления ор..
ВИДАТОКС - VIDATOX  - 1 шт.
ВИДАТОКС - VIDATOX - 1 шт.
Отзывы
Спасибо. Реально помогает при профилактике онкологии, а также для поддержания и..
 ВИДАТОКС - VIDATOX - 3 шт.
ВИДАТОКС - VIDATOX - 3 шт.
Отзывы
Вот у вас написано, что сегодня на территории Кубы функционирует тринадцать ферм..
ВИДАТОКС - VIDATOX - 2 шт.
ВИДАТОКС - VIDATOX - 2 шт.
Отзывы
Препарат получила, спасибо,! Надеюсь на отличный результат! Даже уверенна в эт..
ВИДАТОКС - VIDATOX  - 1 шт.
ВИДАТОКС - VIDATOX - 1 шт.
Отзывы
Кубинский препарат Видатокс – это эффективное очищающее натуральное средство, ко..
ВИДАТОКС - VIDATOX  - 1 шт.
ВИДАТОКС - VIDATOX - 1 шт.
Отзывы
Ну что я могу сказать об этом средстве? Помогает в большинстве случаев как я мон..
ВИДАТОКС - VIDATOX - 4 шт.
ВИДАТОКС - VIDATOX - 4 шт.
Отзывы
Я беременна первым ребёнком и мне поставили диагноз рак молочной железы. Сказали..

Результаты применения VIDATOX® 30 CH при лечении онкологии.

 

 

Использование Vidatox® 30 CH

Результаты использования Vidatox® 30 CH больными с онкологическими патологиями.


Автор: Магистр. Фабио де Хесус Линарес Pazos.
LABIOFAM Сьенфуэгос.

 

Введение:
Рак является одной из основных причин смертности во всем мире: в 2005 году 7,6 млн. летальных исходов были вызваны раком, и предполагается, что более 84 миллионов умрут к 2015 году, хотя более 40% всех случаев рака являются прогнозируемыми.

Эта патология была в течение более чем трех десятилетий второй причиной смертности на Кубе для всех  возрастных категорий, включая детей с первых лет жизни, при  этом ситуация изменилась немного в последнее время.

Различные исследователи изучают  патологию рака и зависимоть от общей смертности и / или риска умереть от болезней. Все они подтвердили устойчивый рост заболеаемости онкологией в настоящее время.
В целях своевременного выявления болезни, лечение и ухода за пациентами, страдающими от рака, Международный центр исследований рака (МАИР) ВОЗ обеспечивает ученых не только научными данными о причинах и механизмах развития болезни, но и способствует исследованиям, чтобы найти способ ее лечения.

В этой связи, Куба представила препарат для применения альтернативных методов лечения онкологии  -  как яд скорпиона Rhopalurus junceus, который является в гомеопатическим средством.
Использование яда эндемичных видов скорпиона восходит к началу девятнадцатого века, когда яд был  впервые опробован  в качестве потенциального противоопухолевого средства. В этой связи, исследования, проведенного Business Group LABIOFAM доказали, что яд scorpion Rhopalurus junceus и фракции молекулярной массы ниже 5 кДа оказывает значительное подавляющее воздействие на опухолевые клетки эпителиального происхождения. Это делает Vidatox® 30 СН  дополнительным средством для лечения рака.


Цель настоящего документа является предоставление научных доказательств, что характеризуют влияние Vidatox® 30 CH для конкретного онкологического лечения.
 

Методы
Ретроспективное исследование о влиянии Vidatox® 30 CH проводилось на 174 добровольных пациентов на Кубе, которые проходили лечение препаратом с 2008 года до 2010 года при дозе 5 капель каждые 12 часов под язык.

 

Критерии
1. Пациенты были диагностированы с помощью  различных средств и методик.
2. Пациенты проходили различные виды онкологических лечений.
3. Пациенты проходили предварительное анкетирование.

 

Исключения:
1. Проводились исследования на пациентах, у которых был подтвержден онкологический диагноз.
2. Все пациенты имели отрицательный тест на беременность.
3. Исключались дети в возрасте до одного года

 

 

АНГЛИЙСКАЯ (ПОЛНАЯ) версия:

 

 

Use of VIDATOX® 30 CH

 

Results of the use of   VIDATOX® 30 CH in patients carrying oncological pathologies.

Autor: MSc. Fabio de Jesús Linares Pazos.

LABIOFAM branch Cienfuegos.

Introduction:

Cancer is one the main causes of mortality worldwide: in 2005 7,6 million deaths caused by cancer were reported, and it is estimated that additional 84 millions will die by 2015, even though more than 40% of all cancer are predictable1. This pathology has been, for more than three decades, the second cause of death in Cuba for all ages and the first regarding lost years of life, though the situation has changed a little bit.2

Different researchers have studied this important pathology and the cancer caused general mortality and/or risk of dying from this disease in the Cuban population3-5. All of them confirmed the sustained increased of this disease to the present date.

In order to improve timely detection, treatment and care of patients suffering from cancer, the International Center of Cancer Research (CIIC) of WHO provides not only scientific evidence on the causes and mechanisms of the development of the disease, but also favors researches to find a way  to treat it. In this regard, Cuba has made incursions in the application of alternative therapies, like the venom of scorpion Rhopalurus junceus, in homeopathic presentation.

The use of the venom of this endemic species dates back to the beginning of the XIX century, when was seen for the first time the potential as antitumoral agent. In this regard, researches conducted by the Business Group LABIOFAM proved that, both the venom of   scorpionRhopalurus junceus and the fractions of molecular mass lower than 5 KDa, have a significant toxicity on tumoral cells of epithelial origin. This, coupled with the good used of homeopathic therapies to favour the self-healing reaction of a sick organism, make VIDATOX® 30 CH a complementary option to considered for the treatment of cancer.

Having this in mind, the objective of this paper is to provide scientific evidence that contributes to characterize the effect of VIDATOX® 30 CH as coadjutant of the specific oncological therapy.

Methods

A retrospective study on the effect of VIDATOX® 30 CH was conducted on 174 volunteer patients that received the treatment from 2008 until 2010. The dose administered in all cases was of 5 sublingual drops every 12 hours

Inclusion criteria

  1. To have been diagnosed by one or various diagnosis means.
  2. To have been submitted to different established oncological treatments.
  3. To have answer the pre-elaborated questionnaire.

Exclusion criteria

  1. Not having confirmative diagnosis of malign ant tumoral pathologies.
  2. To a have  positive diagnosis for pregnancy

3.   Children under one year of age

Indicators to bear in mind

Demographic characteristics of the population being studied

Results

Fig. 1 shows the distribution of the simple by neoplasia family and metastasis reference in each case. Note a higher presence of carcinomas and adenocarcinomas and prevalence of metastasis. This distribution by neoplasia family of the sample matches the RNC5 reports.

 

Figure 1. Distribution of neoplasic families and metastasis in the studied population.

The country and sex ration is shown in Figure 2. note that Cuban patients prevail with 128 cases for 73,56% followed by Mexico with 9.20 % and Colombia with 6,90%. Regarding sex there is a slight predominance of women with 92 cases over men with 82, for 1.1 ratios. This ratio differs in Mexico with 12 men and 4 women under treatment for a ration of 3.

Figure 2. Distribution of patients by country and sex.

Figure 3 shows oncological treatments received by patients object of this study who are grouped by neoplasic families, the treatments include surgery, chemotherapy, radiotherapy, therapeutic vaccines. Note the predominance of chemotherapy, surgery and radiotherapy, similar to international situation.1  The cases of adenocarcinoma, carcinoma and neurohistone present patients for each therapeutic variant mentioned.

Figure 3 Specific oncological treatments according to the oncological family in the studied sample.

Fig. 4 shows the distribution of patients by primary affected organ and oncological family, with predominance of lung, prostate, colon, breast, lymphoid tissue, pancreas, uterus, brain, skin, recto, stomach and testicle among the 33 indexed locations.

Some of the results obtained through the RNC informative system are:

The results of our simple match what is established by RNC.

Tables # 5, # 6 and # 7  show the symptoms reported by sex according to the primary organ and the improvements in follow up consultations.

Due to the lack of imageonological reports and other tests of confirmation of the evolution of these patients, the information provided here is presented based on symptoms presented at the beginning and modified or not, by the effect of our drug, which is being studied.

We have not intentionally adapted the symptoms to the classic medical terminology and take them as stated in discharge sheets, summarized medical records and case studies conducted by us, recording a total of 57 different symptoms, which are shown in the above-mentioned tables and grouped by affected primary organ. The organs with higher prevalence are shown in the study.

The most important symptoms for each case are:

Note: For all cases we have removed from the list those patients who were and remain asymptomatic

Table 8 shows the survival of sampled patients from the date of diagnosis for each case until February 2010, by age and sex. Note there is a predominance of patients under 60 and more female cases up to 64 and more patients whose survival is more than 25 months.

 

Sex

   

Survival in months

Age

f

m

n

%

<=6

12

18

24

>25

n

<60

56

34

90

52%

5

11

16

13

46

90

60-64

10

15

25

14%

2

4

1

3

12

25

65-69

6

8

14

8%

 

1

3

3

7

14

70-74

8

12

20

11%

4

5

2

1

8

20

75-80

7

5

12

7%

 

2

2

1

8

12

>80

5

8

13

7%

3

3

1

2

5

13

n

92

82

174

 

14

26

25

23

86

174

Table 8.

Analysis by groups of population

Adults (25-59 years): This group represents 50% of the population. About 20% of deaths occurred at these ages or a rate of 2.8 per 1 000 inhabitants in 2000. the first causes of death were malignant tumors, heart diseases and accidents with 57% deaths. For all cases the male mortality prevailed except for malignant tumors.

Senior adults (60 years or more):  75% of deaths occurred in this group in 2000. The main causes were heart diseases, malignant tumors and cerebrovascular diseases with 63% of the total.

Table 9 shows the improvement of patients in follow up consultations for 3, 6, 9, 12 months and more than one year. The highest percentages are in the groups under or equal to 60 and from 60 to 64 with more cases of improvement after six months of treatment, followed by improvement at three months. This group includes many of the patients that start the treatment in the last semester of 2009, followed then by the group that keeps improvement up to 9 month.

 

Sex

   

Improvement in months

Age

f

m

n

%

3

6

9

12

+ 1 year

<60

56

34

90

52%

17

27

14

7

5

60-64

10

15

25

14%

4

10

4

2

2

65-69

6

8

14

8%

1

3

4

1

1

70-74

8

12

20

11%

4

2

1

1

3

75-80

7

5

12

7%

2

5

1

   

>80

5

8

13

7%

2

7

1

1

2

n

92

82

174

 

30

54

25

12

13

Table 9.

Table 10  calculates the survival of the sample by the actuarial method, determining an accumulated probability of survival of 96%.

time period

Alive at the beginning of the time period

Deaths during the time period

Alive abandonment  or loss of follow up 

probability of death or event

Probability of being free in the event

Accumulated probability of survival

months

(n)

(d)

(w)

q = d / (n[w/2])

pi = 1 – q

s = pi · pi-1

3

174

1

 

0.01

0.99

0.99

6

84

2

40

0.03

0.97

0.96

9

25

   

0.00

1.00

0.96

12

12

   

0.00

1.00

0.96

12 +

13

   

0.00

1.00

0.96

taken from follow up consultations

Table 10.

Table 11 refers to those patients not suitable for a specific oncological treatment due to the advanced age and prognosis. The table reflects the survival index by grouping them by affected primary organ and evaluating them at scales of under or equal to six months and up to 25 months, with a predominance of patients with lung, colon, liver, pancreas and prostate cancer.

 

Survival

 

Organ

<=6

12

18

24

>25

n

%

Brain

 

1

     

1

3%

Colon

1

 

1

 

1

3

9%

Liver

     

1

2

3

9%

Breast

       

1

1

3%

Mediastinum

 

1

     

1

3%

Nerve.

 

1

     

1

3%

Pancreas

1

1

   

1

3

9%

Prostate

1

   

1

1

3

9%

Lung

2

2

4

3

2

13

37%

Recto

     

1

 

1

3%

Blood

     

1

 

1

3%

Lymphoid tissue

       

1

1

3%

Thyroid

     

1

 

1

3%

Vagina

1

       

1

3%

Bladder

   

1

   

1

3%

n

6

6

6

8

9

35

 

Table 11.

Table 12 shows the analgesic effect of our medicine in patients referring pain, according to the scale established in the Haematology and Orthopaedics  Services of “Hermanos Ameijeiras” Clinical Surgical Hospital. A significant improvement effect is note in patients with severe pain (2 in scale) 62%, taking them to the minimal or moderate pain condition (1 in scale) 62% or no pain (0 in scale) 27%. It also modified the disabling pain (3 in scale) of three of the five patients included in this group of severe pain (2 in scale)

Analgesic effect

Scale

Before

%

After

%

 

0

   

17

27%

1

19

30%

39

62%

2

39

62%

5

8%

3

5

8%

2

3%

 

63

 

63

 

Table 12.

Note: Scale established in the Haematology and Orthopaedics  Services of “Hermanos Ameijeiras” Clinical Surgical Hospital

Generally, patients who have received the sample have witnessed :

Conclusions:

Using this homeopathic biotherapy, we have:

Without going through the unwanted symptoms caused today by radiation and cytostatic therapies, our patients receive.

Bibliography:

  1. WHO. World Day against Cancer: action to prevent 8 million cancer deaths from now to 2015. Available in: http://www.who.int/mediacentre/news/
    releases/2006/pr06/es/index.html
    .
  1. Ministry of Public Health; National Division of Statistics and Medical Records. Health Statistical Annual Report.  1970 – 2006. Havana. (Cuba): MINSAP; 1971 – 2007.
  1. Mendoza M, Caceres CL, Jimenez H. Cancer mortality in Camagűey, from 1980 to 1984. Rev. Cubana Oncol. 1987; 3 (3).
  1. Gonzalez L, Lemes JJ. Characteristics of cancer mortality. Granma 2000. Cuban magazine of oncology. 2000; 16 (1): 21 – 3.
  1. Sanso S. F., Alonso G. P., Torres V. R. Cancer Mortality in Cuba. Cuban Magazine on Public Health. 2010; 36 (1).